Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY2020 Earnings Presentation
9 slides from Aurobindo Pharma's earnings presentation, Aug 7, 2019
Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
~ AUROBINDO August?,2019 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Sandra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI·400 051 25th floor, Dalal Street, MUMBAI·400 001 Company Code No. AUROPHARMA C
Slide 2: Leading Vertically Integrated Generic Player – Q1FY19-20 Earnings Presentation
LEADING VERTICALLY INTEGRATED GENERIC PLAYER Q1FY19-20 Earnings Presentation
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 4: Consolidated Financial & Business Highlights – Q1FY20
Consolidated Financial & Business Highlights – Q1FY20 Key Financial Highlights • Revenue from operations at INR 5,444.6 crore, witnessed a strong growth of 28.1% YoY • EBIDTA before forex and other income at INR 1,146.4 crore, an increase of 47.1% YoY; EBITDA margin is at 21.1% • Net Profit after JV
Slide 5: US Filings Snapshot
US Filings Snapshot Cumulative ANDA Filings and Approvals Addressable 551 541 Therapy ANDAs Market Size 478 (US$ Bn) 138 139 429 Anti Diabetic 19 9.5 As per IQVIA Jun 2019, 376 398 117 26 26 ARV** 42 5.5 addressable Market at US$ 115 147 34 CNS 94 24.7 98.0 Bn including ~US$ 67.1 183 38 Controlled S
Slide 6: Consolidated Financial Performance – Q1FY20 YoY
Consolidated Financial Performance – Q1FY20 YoY Q1 Q1 % Value INR Cr Revenue from Operations - Breakup FY20 FY19 Chg Value in INR Cr Q1FY20 Q1FY19 % Chg Formulations 4,712.0 3,500.8 34.6 USA 2,688.4 1,889.6 42.3 API 732.2 748.0 -2.1 EU 1,391.6 1,199.1 16.1 Formulations % of revenue 86.6% 82.4% Growt
Slide 7: Consolidated Financial Performance – Q1FY20 QoQ
Consolidated Financial Performance – Q1FY20 QoQ Q1 Q4 % Value INR Cr Revenue from Operations - Breakup FY20 FY19 Chg Value in INR Cr Q1FY20 Q4FY19 % Chg Formulations 4,712.0 4,373.6 7.7 USA 2,688.4 2,481.1 8.4 API 732.2 916.8 -20.1 EU 1,391.6 1,311.8 6.1 Formulations % of revenue 86.6% 82.7% Growth
Slide 8: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Mar-18 Mar-19 Jun-19 Closing Rate1 US$ = 66.25 64.85 65.17 69.155 69.020 INR Fx Loan restated in 4,956.7 3,121.5 4,766.9 6,959.0 5,865.4 748 481 731 1,006 850 INR Rupee Loan 46.9 244.8 4.1 8.1 17.8 Sales Tax Deferment 41.9 0.0 0.0 0.0 0.0
Slide 9: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Registered Of